Simba Gill - May 7, 2023 Form 4/A - Amendment Insider Report for Evelo Biosciences, Inc. (EVLO)

Role: President & CEO, Director
Signature: /s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
Stock symbol: EVLO
Transactions as of: May 7, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 5/10/2023, 05:11 PM
Date Of Original Report: May 9, 2023
Previous filing: Feb 9, 2023
Next filing: May 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVLO	Restricted Stock Units	Options Exercise	$0	-23.4K	-6.25%	$0.00	352K	May 7, 2023	Common Stock	23.4K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2	The RSUs vest in sixteen (16) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the fourth anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. The RSUs have no expiration date.

Remarks:

This Form 4/A is being filed to disclose the disposition of 23,437 RSUs. Column 5 of Table II in the Form 4 filed on May 9, 2023 inadvertently and improperly showed that these securities were acquired. Column 9 of Table II remains unchanged from the May 9, 2023 filing.